About AVT
Browse Articles
Customer Services

Original article

Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study

Odile Launay, Michel Tod, Inga Tschöpe, Ali Si-Mohamed, Linda Bélarbi, Charlotte Charpentier, Cécile Goujard, Anne-Marie Taburet, Olivier Lortholary, Valériane Leroy, Laurent Bélec, the ANRS EP24 GYNODYN Study Group

Corresponding author name: Odile Launay
Corresponding author e-mail: odile.launay@cch.aphp.fr

Citation: Antiviral Therapy 2011; 16:843-852
doi: 10.3851/IMP1856

Date accepted: 07 January 2011
Date published online: 20 July 2011


Background: The female genital tract constitutes a reservoir for HIV providing active production of both cell-free HIV RNA and cell-associated DNA within the cervicovaginal secretions. The objective of this study was to prospectively assess residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women initiating HAART over an 18-month period.

Methods: Paired blood and cervicovaginal lavage samples were collected at inclusion and 1, 6, 12 and 18 months after HAART initiation, in 23 women in first-line HAART and six women in virological failure, for measurement of HIV-1 RNA and HIV-1 DNA shedding and/or drug concentrations.

Results: A dramatic decrease of HIV-1 RNA and HIV-1 DNA occurred in both blood and cervicovaginal samples over the first 6 months on HAART, followed by a shelf up to 18 months, independently of the drugs’ genital pharmacokinetics. While cervicovaginal HIV-1 RNA became undetectable in >90% of women from 6 months on HAART, genital HIV-1 DNA remained frequently detectable (27–50%). Nearly 40% of women with sustained undetectable plasma HIV-1 RNA after 6–18 months on HAART harboured transient HIV-1 RNA (15% of women) or HIV-1 DNA (31% of women) in their genital secretions.

Conclusions: Low-level cervicovaginal HIV-1 shedding is frequently evidenced in HAART-treated women with transient HIV-1 RNA and persistent HIV-1 DNA despite a systemic control of viral replication, resulting in possible residual genital infectivity.


Copyright © Nucleus Global 2018. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.